Pyxis Oncology, Inc.

NasdaqGS:PYXS Stock Report

Market Cap: US$124.2m

Pyxis Oncology Future Growth

Future criteria checks 2/6

Pyxis Oncology is forecast to grow earnings and revenue by 8.6% and 60.8% per annum respectively while EPS is expected to grow by 20.8% per annum.

Key information

8.6%

Earnings growth rate

20.81%

EPS growth rate

Biotechs earnings growth25.2%
Revenue growth rate60.8%
Future return on equityn/a
Analyst coverage

Good

Last updated18 May 2026

Recent future growth updates

Recent updates

Seeking Alpha • Sep 12

Pyxis Oncology: Readouts Ahead, Although Cash Might Dwindle (Rating Downgrade)

Summary PYXS is developing micvotabart pelidotin for head and neck squamous cell carcinoma, with key clinical readouts expected in H2'25 and H1'26. While micvotabart pelidotin has shown early efficacy and tolerability, limited patient data and competition raise concerns. PYXS has cash runway into H2'26 but faces risk from potential clinical disappointments, competitor updates, and possible dilutive fundraising. Read the full article on Seeking Alpha
Analysis Article • Jun 19

Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Dec 07

Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead

Summary Pyxis Oncology's lead candidate, PYX-201, showed promising response rates in Phase 1 trials but raised safety concerns due to a patient's death. The company’s valuation appears deeply discounted, with a P/B ratio of 0.7 compared to a sector median of 2.4, reflecting market pessimism. PYX-201's ongoing trials and upcoming catalysts in 2025-2026 are crucial for addressing safety concerns and demonstrating efficacy across multiple cancer types. Investors should consider PYXS's financial runway, speculative nature, and potential for significant stock appreciation if future trial results are favorable. Despite setbacks, PYXS's valuation appears deeply oversold, presenting a speculative "Buy" opportunity due to its robust pipeline and potential revenue from licensing. Read the full article on Seeking Alpha
Seeking Alpha • Sep 13

Moment Of Truth Approaches For Pyxis Oncology

Summary Pyxis Oncology is an antibody and antibody-drug conjugate developer with initial results from two clinical trials ahead in 2024. Data from a phase 1 study of PYX-201, an ADC targeting extra domain B of fibronectin, in multiple tumor types, are expected in fall 2024. Data from a phase 1 study of PYX-106, an anti-Siglec-15 antibody, in multiple tumor types, are expected by year-end 2024. PYXS estimates its current cash will last until H2'26. Read the full article on Seeking Alpha
Seeking Alpha • Jun 10

Pyxis Oncology: Promising Research Amid Cash Constraints

Summary Pyxis Oncology develops innovative therapeutics for hard-to-treat cancers using antibody-drug conjugates and immunotherapies. The company's pipeline includes PYX-201 and PYX-106, targeting multiple solid tumor types, with preliminary data expected in 2024. Pyxis recently announced a workforce reduction and sold the royalties and commercialization rights of Beovu to extend its cash runway. Despite innovative technology, PYXS faces financial constraints and early-stage development risks. A neutral stance on PYXS is prudent due to speculative IP and potential shareholder dilution. Read the full article on Seeking Alpha
Seeking Alpha • Mar 28

Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait

Summary Pyxis Oncology is developing antibodies and antibody-drug conjugates for various tumor types. Initial data from the phase 1 trials of PYX-106 and PYX-201 are now expected in H2'24 and fall 2024 respectively. PYXS raised $50M in gross proceeds with a private placement in February 2024 and is cashed into H2'26. Read the full article on Seeking Alpha
Seeking Alpha • Jan 18

Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis

Summary Pyxis Oncology is a biotech company focused on developing immunotherapies for cancer treatment. Their most advanced pipeline project is sotigalimab, a CD40 agonist, which has shown promising results in melanoma and liposarcoma. The company has enough funds to continue operating for 5-6 quarters, but future funding may require dilutive financing. Read the full article on Seeking Alpha
Analysis Article • Feb 18

Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Sep 01

Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 15

Pyxis Oncology GAAP EPS of -$0.79 beats by $0.06

Pyxis Oncology press release (NASDAQ:PYXS): Q2 GAAP EPS of -$0.79 beats by $0.06. Pyxis Oncology had cash and cash equivalents of $223 million as of June 30, 2022, and approximately $207 million (preliminary, unaudited) as of August 15, 2022, which is expected to fund operations through the second half of 2024.
Analysis Article • Apr 13

We're Hopeful That Pyxis Oncology (NASDAQ:PYXS) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Earnings and Revenue Growth Forecasts

NasdaqGS:PYXS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202812-114N/AN/A9
12/31/20273-107N/AN/A9
12/31/20260-93N/AN/A9
3/31/202614-82N/AN/AN/A
12/31/202514-80-64-64N/A
9/30/20253-97-72-72N/A
6/30/20253-96-74-74N/A
3/31/2025N/A-95-59-59N/A
12/31/202416-77-58-58N/A
9/30/202416-57-54-54N/A
6/30/202416-59-57-57N/A
3/31/202416-58-67-65N/A
12/31/2023N/A-74-77-71N/A
9/30/2023N/A-94-81-73N/A
6/30/2023N/A-99-89-76N/A
3/31/2023N/A-109-99-88N/A
12/31/2022N/A-121-96-89N/A
9/30/2022N/A-101-89-84N/A
6/30/2022N/A-88-71-71N/A
3/31/2022N/A-71-45-44N/A
12/31/2021N/A-76-36-35N/A
9/30/2021N/A-64-27-26N/A
6/30/2021N/A-53-22-22N/A
3/31/2021N/A-47-28-27N/A
12/31/2020N/A-13-12-10N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PYXS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PYXS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PYXS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PYXS's revenue (60.8% per year) is forecast to grow faster than the US market (11.7% per year).

High Growth Revenue: PYXS's revenue (60.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PYXS's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/26 15:42
End of Day Share Price 2026/05/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pyxis Oncology, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Bradley CaninoGuggenheim Securities, LLC
Swayampakula RamakanthH.C. Wainwright & Co.